The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 14, 2014
Filed:
Nov. 02, 2006
Liang Xu, Arlington, VA (US);
Cheng-cheng Huang, Arlington, VA (US);
William Alexander, Rockville, MD (US);
Wenhua Tang, Arlington, VA (US);
Esther H. Chang, Chevy Chase, MD (US);
Liang Xu, Arlington, VA (US);
Cheng-Cheng Huang, Arlington, VA (US);
William Alexander, Rockville, MD (US);
WenHua Tang, Arlington, VA (US);
Esther H. Chang, Chevy Chase, MD (US);
SynerGene Therapeutics, Inc., Washington, DC (US);
Georgetown University, Washington, DC (US);
Abstract
A targeted vector allowing enhanced gene transfer to human hepato-cellular carcinoma (HCC) cells in vitro was developed using cationic liposomes covalently conjugated with the mAb AF-20. This high affinity antibody recognizes a rapidly internalized 180 kDa cell surface glycoprotein which is abundantly expressed on the surface of human HCC and other cancer cells. Quantitative binding analysis of liposomes with target cells by flow cytometry showed specific association of mAb-targeted liposomes with human HCC cells. Using mAb-targeted cationic liposomes containing 20% DOTAP, in the presence or absence of serum, gene expression in HuH-7 cells was enhanced up to 40-fold as compared to liposomes conjugated with an isotype-matched non-relevant control antibody. Transfection specificity was not observed in a control cell line that does not express the antigen recognized by mAb AF-20. This study demonstrates that cationic liposome formulations can be targeted with monoclonal antibodies (mAbs) to enhance specific in vitro gene delivery and expression in the presence or absence of serum.